Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS · Delayed Price · Currency is USD
0.1002
+0.0002 (0.15%)
Mar 28, 2025, 3:57 PM EST

PVCT Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Revenue
0.620.560.99--
Upgrade
Revenue Growth (YoY)
10.66%-43.61%---
Upgrade
Cost of Revenue
-1.72.312.52-
Upgrade
Gross Profit
0.62-1.14-1.32-2.52-
Upgrade
Selling, General & Admin
3.151.361.552.122.21
Upgrade
Research & Development
1.99---2.72
Upgrade
Operating Expenses
5.141.361.552.124.94
Upgrade
Operating Income
-4.52-2.5-2.87-4.64-4.94
Upgrade
Interest Expense
-0.24-0.22-0.16-0.96-1.75
Upgrade
Interest & Investment Income
----0
Upgrade
EBT Excluding Unusual Items
-4.76-2.71-3.03-5.6-6.68
Upgrade
Legal Settlements
--0.39-0.52--
Upgrade
Other Unusual Items
---0.060
Upgrade
Pretax Income
-4.76-3.1-3.55-5.54-6.68
Upgrade
Net Income
-4.76-3.1-3.55-5.54-6.68
Upgrade
Net Income to Common
-4.76-3.1-3.55-5.54-6.68
Upgrade
Shares Outstanding (Basic)
420420419408393
Upgrade
Shares Outstanding (Diluted)
420420419408393
Upgrade
Shares Change (YoY)
0.07%0.01%2.76%3.81%1.72%
Upgrade
EPS (Basic)
-0.01-0.01-0.01-0.01-0.02
Upgrade
EPS (Diluted)
-0.01-0.01-0.01-0.01-0.02
Upgrade
Free Cash Flow
-3.28-2.57-3.04-1.01-4.09
Upgrade
Free Cash Flow Per Share
-0.01-0.01-0.01-0.00-0.01
Upgrade
Gross Margin
100.00%-204.69%-133.60%--
Upgrade
Operating Margin
-732.91%-447.97%-290.12%--
Upgrade
Profit Margin
-771.65%-556.16%-359.41%--
Upgrade
Free Cash Flow Margin
-532.15%-461.17%-307.52%--
Upgrade
EBITDA
-4.52-2.49-2.86-4.63-4.69
Upgrade
EBITDA Margin
---289.01%--
Upgrade
D&A For EBITDA
0.010.010.010.010.24
Upgrade
EBIT
-4.52-2.5-2.87-4.64-4.94
Upgrade
EBIT Margin
---290.12%--
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.